XENON PHARMACEUTICALS INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
XENON PHARMACEUTICALS INC. (XENE) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 58.00% for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2026-08-06
- XENON PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2026-06-30 was 58.00%, a 4.92% decline year-over-year.
- XENON PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2026-03-31 was 58.00%, a 4.92% decline year-over-year.
- XENON PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2025-09-30 was 62.00%, a 6.06% decline year-over-year.
- XENON PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2025-06-30 was 61.00%, a 6.15% decline year-over-year.
- XENON PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2025 was 61.00%, a 7.58% decline from fiscal 2024.
- XENON PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2024 was 66.00%, a 4.35% decline from fiscal 2023.
- XENON PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2023 was 69.00%, a 1.43% decline from fiscal 2022.
- XENON PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2022 was 70.00%, a 2.94% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month |
|---|---|---|---|---|
| 2026-06-30 | 58.00% 10-Q · filed 2026-08-06 | 58.00% 10-Q · filed 2026-08-06 | ||
| 2026-03-31 | 58.00% 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | 61.00% 10-K · filed 2026-02-26 | |||
| 2025-09-30 | 62.00% 10-Q · filed 2025-11-03 | 61.00% 10-Q · filed 2025-11-03 | ||
| 2025-06-30 | 61.00% 10-Q · filed 2026-08-06 | 61.00% 10-Q · filed 2026-08-06 | ||
| 2025-03-31 | 61.00% 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | 66.00% 10-K · filed 2026-02-26 | |||
| 2024-09-30 | 66.00% 10-Q · filed 2025-11-03 | 66.00% 10-Q · filed 2025-11-03 | ||
| 2024-06-30 | 65.00% 10-Q · filed 2025-08-11 | 66.00% 10-Q · filed 2025-08-11 | ||
| 2024-03-31 | 67.00% 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | 69.00% 10-K · filed 2026-02-26 | |||
| 2023-09-30 | 68.00% 10-Q · filed 2023-11-08 | 69.00% 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | 69.00% 10-Q · filed 2024-08-08 | 69.00% 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | 69.00% 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | 70.00% 10-K · filed 2025-02-27 | |||
| 2022-09-30 | 70.00% 10-Q · filed 2023-11-08 | 70.00% 10-Q · filed 2023-11-08 | ||
| 2022-06-30 | 70.00% 10-Q · filed 2023-08-09 | 70.00% 10-Q · filed 2023-08-09 | ||
| 2022-03-31 | 70.00% 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | 68.00% 10-K · filed 2024-02-29 | |||
| 2021-09-30 | 68.00% 10-Q · filed 2022-11-08 | 68.00% 10-Q · filed 2022-11-08 | ||
| 2021-06-30 | 69.00% 10-Q · filed 2022-08-09 | 68.00% 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | 68.00% 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | 68.00% 10-K · filed 2023-03-01 | |||
| 2020-09-30 | 68.00% 10-Q · filed 2021-11-10 | 68.00% 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | 68.00% 10-Q · filed 2021-08-11 | 68.00% 10-Q · filed 2021-08-11 | ||
| 2020-03-31 | 68.00% 10-Q · filed 2021-05-11 | |||
| 2019-12-31 | 69.00% 10-K · filed 2021-03-01 | |||
| 2019-09-30 | 69.00% 10-Q · filed 2020-11-05 | 69.00% 10-Q · filed 2020-11-05 | ||
| 2019-06-30 | 76.00% 10-Q · filed 2020-08-06 | |||
| 2019-03-31 | 76.00% 10-Q/A · filed 2020-05-26 | |||
| 2018-12-31 | 75.00% 10-K · filed 2020-03-09 | |||
| 2018-09-30 | 76.00% 10-Q · filed 2019-11-05 | 75.00% 10-Q · filed 2019-11-05 | ||
| 2018-06-30 | 75.00% 10-Q · filed 2019-08-06 | 75.00% 10-Q · filed 2019-08-06 | ||
| 2018-03-31 | 75.00% 10-Q · filed 2019-05-07 | |||
| 2017-12-31 | 80.00% 10-K · filed 2019-03-06 | |||
| 2017-09-30 | 81.00% 10-Q · filed 2018-11-06 | 81.00% 10-Q · filed 2018-11-06 | ||
| 2017-06-30 | 81.00% 10-Q · filed 2018-08-07 | 81.00% 10-Q · filed 2018-08-07 | ||
| 2017-03-31 | 81.00% 10-Q · filed 2018-05-08 | |||
| 2016-12-31 | 75.00% 10-K · filed 2018-03-07 | |||
| 2016-09-30 | 75.00% 10-Q · filed 2017-11-07 | 75.00% 10-Q · filed 2017-11-07 | ||
| 2016-06-30 | 74.00% 10-Q · filed 2017-08-03 | 75.00% 10-Q · filed 2017-08-03 | ||
| 2016-03-31 | 75.00% 10-Q · filed 2017-05-09 | |||
| 2015-12-31 | 75.00% 10-K · filed 2018-03-07 | |||
| 2015-09-30 | 67.00% 10-Q · filed 2016-11-03 | 75.00% 10-Q · filed 2016-11-03 | ||
| 2015-06-30 | 75.00% 10-Q · filed 2016-08-03 | 75.00% 10-Q · filed 2016-08-03 | ||
| 2015-03-31 | 75.00% 10-Q · filed 2016-05-10 | |||
| 2014-12-31 | 73.00% 10-K · filed 2017-03-08 | |||
| 2014-09-30 | 74.00% 10-Q · filed 2015-11-10 | 74.00% 10-Q · filed 2015-11-10 | ||
| 2014-06-30 | 74.00% 10-Q · filed 2015-08-13 | 74.00% 10-Q · filed 2015-08-13 | ||
| 2014-03-31 | 74.00% 10-Q/A · filed 2015-08-13 | |||
| 2013-12-31 | 70.00% 10-K · filed 2016-03-08 | |||
| 2013-09-30 | 70.00% 10-Q · filed 2014-12-15 | 70.00% 10-Q · filed 2014-12-15 | ||
| 2012-12-31 | 70.00% 10-K · filed 2015-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 |